European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), 9713AV Groningen, The Netherlands.
Institute of Biology, College of Science, University of the Philippines Diliman, Quezon City, PH 1101, Philippines.
Hum Reprod Update. 2022 Feb 28;28(2):172-189. doi: 10.1093/humupd/dmab038.
Advanced maternal age is associated with decreased oocyte quantity and quality as well as uterine and placental dysfunctions. These changes lead to infertility, pregnancy complications and birth defects in the offspring. As the mean age of giving birth is increasing worldwide, prevention of age-associated infertility and pregnancy complications, along with the more frequent use of ART, become extremely important. Currently, significant research is being conducted to unravel the mechanisms underlying female reproductive aging. Among the potential mechanisms involved, recent evidence has suggested a contributing role for cellular senescence, a cellular state of irreversible growth arrest characterized by a hypersecretory and pro-inflammatory phenotype. Elucidating the role of senescence in female reproductive aging holds the potential for developing novel and less invasive therapeutic measures to prevent or even reverse female reproductive aging and increase offspring wellbeing.
The review will summarize the positive and negative implications of cellular senescence in the pathophysiology of the female reproductive organs during aging and critically explore the use of novel senotherapeutics aiming to reverse and/or eliminate their detrimental effects. The focus will be on major senescence mechanisms of the ovaries, the uterus, and the placenta, as well as the potential and risks of using senotherapies that have been discovered in recent years.
Data for this review were identified by searches of MEDLINE, PubMed and Google Scholar. References from relevant articles using the search terms 'Cellular Senescence', 'Aging', 'Gestational age', 'Maternal Age', 'Anti-aging', 'Uterus', 'Pregnancy', 'Fertility', 'Infertility', 'Reproduction', 'Implant', 'Senolytic', 'Senostatic', 'Senotherapy' and 'Senotherapeutic' where selected. A total of 182 articles published in English between 2005 and 2020 were included, 27 of which focus on potential senotherapies for reproductive aging. Exclusion criteria were inclusion of the terms 'male' and 'plants'.
Aging is a major determinant of reproductive wellbeing. Cellular senescence is a basic aging mechanism, which can be exploited for therapeutic interventions. Within the last decade, several new strategies for the development and repurposing of drugs targeting senescent cells have emerged, such as modulators of the anti-inflammatory response, oxidative stress, DNA damage, and mitochondria and protein dysfunctions. Several studies of female reproductive aging and senotherapies have been discussed that show promising results for future interventions.
In most countries of the Organization for Economic Co-operation and Development, the average age at which women give birth is above 30 years. Currently, in countries such as the Netherlands, Australia, Spain, Finland, Germany and the UK, birth rates among 30- to 34-year-olds are now higher than in any other age groups. This review will provide new knowledge and scientific advancement on the senescence mechanisms during female reproductive aging, and benefit fundamental and clinical scientists and professionals in the areas of reproduction, cancer, immunobiology and fibrosis.
高龄产妇会导致卵子数量和质量下降,以及子宫和胎盘功能障碍。这些变化会导致不孕、妊娠并发症和后代出生缺陷。随着全球生育年龄的增长,预防与年龄相关的不孕和妊娠并发症以及更频繁地使用辅助生殖技术变得极其重要。目前,正在进行大量研究以揭示女性生殖衰老的潜在机制。在涉及的潜在机制中,最近的证据表明,细胞衰老在女性生殖衰老的病理生理学中起着重要作用,细胞衰老是一种不可逆的生长停滞状态,其特征是过度分泌和促炎表型。阐明衰老在女性生殖衰老中的作用有可能开发出新的、侵入性更小的治疗措施,以预防甚至逆转女性生殖衰老并提高后代的健康水平。
该综述将总结细胞衰老在衰老过程中对女性生殖器官的病理生理学的积极和消极影响,并批判性地探讨使用旨在逆转和/或消除其有害影响的新型衰老治疗方法。重点将放在卵巢、子宫和胎盘的主要衰老机制上,以及近年来发现的使用衰老治疗方法的潜力和风险。
本综述的数据通过 MEDLINE、PubMed 和 Google Scholar 进行检索。使用“细胞衰老”、“衰老”、“胎龄”、“母亲年龄”、“抗衰老”、“子宫”、“妊娠”、“生育”、“不孕”、“生殖”、“植入”、“衰老裂解”、“衰老稳定”、“衰老治疗”和“衰老治疗”等搜索词,从相关文章中检索到了本综述的数据。共纳入了 2005 年至 2020 年间发表的 182 篇英文文章,其中 27 篇重点介绍了生殖衰老的潜在衰老治疗方法。排除标准包括纳入“男性”和“植物”的术语。
衰老是生殖健康的主要决定因素。细胞衰老作为一种基本的衰老机制,可以被利用来进行治疗干预。在过去十年中,已经出现了几种针对衰老细胞的新药物开发和再利用策略,例如针对抗炎反应、氧化应激、DNA 损伤以及线粒体和蛋白质功能障碍的调节剂。讨论了一些关于女性生殖衰老和衰老治疗的研究,这些研究为未来的干预措施提供了有希望的结果。
在经济合作与发展组织的大多数国家,女性生育的平均年龄都在 30 岁以上。目前,在荷兰、澳大利亚、西班牙、芬兰、德国和英国等国家,30 至 34 岁女性的出生率现在高于任何其他年龄组。本综述将为女性生殖衰老过程中的衰老机制提供新知识和科学进展,使生殖、癌症、免疫生物学和纤维化领域的基础和临床科学家及专业人员受益。